Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM( Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen Ambulatory Blood Pressure Measurement) Trial

作者：Ruschitzka Frank^*; Borer Jeffrey S; Krum Henry; Flammer Andreas J; Yeomans Neville D; Libby Peter; Luscher Thomas F; Solomon Daniel H; Husni M Elaine; Graham David Y; Davey Deborah A; Wisniewski Lisa M; Menon Venu; Fayyad Rana; Beckerman Bruce; Iorga Dinu; Lincoff A Michael; Nissen Steven E

来源：European Heart Journal, 2017, 38(44): 3282-3292.

DOI：10.1093/eurheartj/ehx508

• Hypertension
• Non-steroidal anti-inflammatory drugs
• Cardiovascular risk
• Selective cyclooxygenase-2 (COX-2) inhibitors
• Osteoarthritis
• Pain

Aims Non-steroidal anti-inflammatory drugs (NSAIDs), both non-selective and selective cyclooxygenase-2 (COX-2) inhibitors, are among the most widely prescribed drugs worldwide, but associate with increased blood pressure (BP) and adverse cardiovascular (CV) events. PRECISION-ABPM, a substudy of PRECISION was conducted at 60 sites, to determine BP effects of the selective COX-2 inhibitor celecoxib vs. the non-selective NSAIDs naproxen and ibuprofen.
Methods and results In this double-blind, randomized, multicentre non-inferiority CV-safety trial, 444 patients (mean age 62 +/- 10 years, 54% female) with osteoarthritis (92%) or rheumatoid arthritis (8%) and evidence of or at increased risk for coronary artery disease received celecoxib (100-200 mg bid), ibuprofen (600-800 mg tid), or naproxen (375-500 mg bid) with matching placebos in a 1: 1: 1 allocation, to assess the effect on 24-h ambulatory BP after 4 months. The change in mean 24-h systolic BP (SBP) in celecoxib, ibuprofen and naproxen-treated patients was -0.3 mmHg [95% confidence interval (CI), -2.25, 1.74], 3.7 (95% CI, 1.72, 5.58) and 1.6 mmHg (95% CI, -0.40, 3.57), respectively. These changes resulted in a difference of -3.9 mmHg (P = 0.0009) between celecoxib and ibuprofen, of -1.8 mmHg (P = 0.12) between celecoxib and naproxen, and of -2.1 mmHg (P = 0.08) between naproxen and ibuprofen. The percentage of patients with normal baseline BP who developed hypertension (mean 24-h SBP >= 130 and/or diastolic BP >= 80 mmHg) was 23.2% for ibuprofen, 19.0% for naproxen, and 10.3% for celecoxib (odds ratio 0.39, P = 0.004 and odds ratio 0.49, P = 0.03 vs. ibuprofen and naproxen, respectively).
Conclusions In PRECISION-ABPM, allocation to the non-selective NSAID ibuprofen, compared with the COX-2 selective inhibitor celecoxib was associated with a significant increase of SBP, and a higher incidence of new-onset hypertension.

• 出版日期2017-11-11